id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2122-0006,FDA,FDA-2020-E-2122,Determination of Regulatory Review Period for Purposes of Patent Extension; TRODELVY,Notice,Determinations,2021-11-24T05:00:00Z,2021,11,2021-11-24T05:00:00Z,2022-05-24T03:59:59Z,2022-01-29T02:00:34Z,2021-25612,0,0,0900006484e7b859
FDA-2020-E-2122-0005,FDA,FDA-2020-E-2122,Letter to U S Patent and Trademark Office,Other,Letter(s),2021-10-22T04:00:00Z,2021,10,2021-10-22T04:00:00Z,,2021-10-26T14:37:10Z,,0,0,0900006484de438a
FDA-2020-E-2122-0004,FDA,FDA-2020-E-2122,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-07-26T04:00:00Z,2021,7,2021-07-26T04:00:00Z,,2021-07-26T17:48:54Z,,0,0,0900006484c0fbd5
FDA-2020-E-2122-0003,FDA,FDA-2020-E-2122,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2021-01-04T05:00:00Z,2021,1,2021-01-04T05:00:00Z,,2021-01-04T17:10:00Z,,0,0,09000064849dc02b